Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Ophthalmology Drugs Market analysis
Part of: Ophthalmology Drugs Market (Global)

The US Ophthalmology Drugs Market was valued at $5114.7 Million in 2025 and projected to reach to $6915.9 Million by 2030, representing a compound annual growth rate of 6.2%. The US ophthalmology drugs market is poised for sustained growth through 2030, supported by an aging population with increasing incidence of chronic eye diseases and strong pharmaceutical innovation.

US Ophthalmology Drugs Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Ophthalmology Drugs Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, high prevalence of age-related eye diseases, and strong pharmaceutical innovation pipelines focused on retinal and anterior segment conditions.
  • Increasing adoption of biologics and specialty drugs in the US is driving market expansion, supported by robust reimbursement frameworks and patient access programs. In the US, the ophthalmology drugs market is characterized by significant investment in research and development for novel therapeutic agents targeting conditions such as dry eye disease, diabetic retinopathy, and age-related macular degeneration.
  • The US pharmaceutical industry's leadership in drug development and the country's aging population are key factors propelling market growth through 2030.
  • Additionally, the US market is witnessing consolidation among major players and increased competition from biosimilar manufacturers, which is reshaping the competitive dynamics of the sector..

Key Market Statistics

  • CAGR (2025-2030) 6.2% CAGR
  • Market Size, 2025 ~USD 5114.7 Million
  • Forecast, 2030 ~USD 6915.9 Million
  • Country US

US Ophthalmology Drugs Market Overview

Market Size & Growth :

The US ophthalmology drugs market is valued at $5,114.7 million in 2025 and is projected to reach $6,915.9 million by 2030, with a steady CAGR of 6.2%, driven by aging demographics and increased disease prevalence.

Advanced Healthcare Infrastructure :

The US benefits from world-class healthcare systems, robust reimbursement mechanisms, and high patient access to innovative ophthalmology treatments, supporting sustained market expansion and premium drug adoption.

Strong Innovation Pipeline :

US pharmaceutical companies are actively developing novel therapies for retinal diseases, age-related macular degeneration, diabetic retinopathy, and anterior segment conditions, with multiple drugs in clinical trials.

Age-Related Disease Prevalence :

Rising prevalence of age-related eye diseases among the growing elderly population in the US is a primary market driver, with conditions like glaucoma and AMD affecting millions of Americans annually.

US Ophthalmology Drugs Market Dynamics

  • Advanced healthcare infrastructure and favorable reimbursement policies enable rapid adoption of new therapies.
  • The market will benefit from expanding treatment options for retinal conditions, glaucoma management, and anterior segment disorders, alongside growing patient awareness and early diagnosis initiatives. Key growth drivers include rising healthcare expenditure, increasing prevalence of diabetes-related eye complications, and continuous R&D investments by major pharmaceutical companies.
  • The competitive landscape will intensify as biosimilars and generic alternatives enter the market, while premium branded drugs maintain strong positions.
  • Strategic partnerships and acquisitions among US-based and international pharma companies will further accelerate market development through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • The US ophthalmology drugs market is valued at $5,114.7 million in 2025 and is expected to reach $6,915.9 million by 2030, growing at a 6.2% CAGR.
    • The US market is driven by an aging population, high prevalence of chronic eye diseases, and strong investment in innovative biologic and specialty drug therapies.
    • The US ophthalmology drugs sector benefits from advanced healthcare infrastructure, robust reimbursement policies, and established patient access programs that support market growth.
    • The US market is experiencing increased competition from biosimilar manufacturers and consolidation among major pharmaceutical players, reshaping the competitive landscape through 2030.

    Ophthalmology Drugs Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment FARICIMAB (Molecule)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.1% from 2025 to 2030
    Largest Segment INTRAVITREAL (Route Of Administration)
    Market Size Base Year (Billions) ~USD 19.55 (2025)
    Revenue Forecast (Billions) ~USD 26.28 (2030)
    Segments Covered Molecule, Modality, Indication, Type, Route Of Administration, End User

    US Ophthalmology Drugs Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Molecule

    • Aflibercept
    • Faricimab
    • Other Molecules
    • Ranibizumab

    By Modality

    • Monoclonal Antibodies & Fusion Proteins
    • Other Modalities
    • Small Molecules

    By Indication

    • Age-Related Macular Degeneration
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Other Indications

    By Type

    • Dry Amd
    • Wet Amd

    By Route Of Administration

    • Intravitreal
    • Other Routes Of Administration
    • Topical

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Specialty Centers

    US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS6277.48138.38716.39298.39968.410678.511365.512140.66.9
    LONG-TERM CARE FACILITIES1291.216571773.81891.22026.42169.62307.924646.8
    SPECIALTY CENTERS552.2692.2722.1749.8781.9814.3841.9872.93.9
    TOTAL8120.810487.511212.111939.312776.713662.314515.415477.66.7

    Target Audience

    • Pharmaceutical Companies : US-based and international pharma firms need market intelligence to guide R&D investments, commercialization strategies, and competitive positioning in the high-value US ophthalmology drugs market.
    • Healthcare Investors & PE Firms : Investment professionals require detailed market data and growth forecasts to evaluate acquisition targets, assess portfolio companies, and identify investment opportunities in US ophthalmology drug manufacturers.
    • Medical Device & Biotech Companies : Biotech firms and device manufacturers need market insights to understand the complementary drug landscape, identify partnership opportunities, and develop integrated treatment solutions for US eye care.
    • Healthcare Consultants & Analysts : Management consultants and equity research analysts require comprehensive US market data to support client advisory work, investment recommendations, and strategic planning in the ophthalmology sector.
    • Hospital & Clinic Administrators : Healthcare facility leaders need market trend data to optimize drug procurement strategies, budget planning, and treatment protocol development aligned with emerging US ophthalmology drug innovations.

    Key Companies in the US Ophthalmology Drugs Market

    CompanyHQOwnershipStrongest segments
    REGENERON PHARMACEUTICALS INC.United StatesPublic CompanyOphthalmology (EYLEA franchise),Immunology / Inflammation (Dupixent, Kevzara),Oncology / Hematology (Libtayo, bispecifics pipeline),
    BAYER AGGermanyPublic CompanyCrop Science (seeds, traits, crop protection, digital ag, services),Pharmaceuticals (cardiology, women’s health, oncology, hematology, ophthalmology, imaging, cell & gene),Consumer Health (OTC, self-care, supplements, dermatology, pain, digestive),
    NOVARTIS AGSwitzerlandPublic CompanyOncology and Hematology (Kisqali, Tafinlar+Mekinist, Pluvicto, Lutathera, Scemblix, Promacta/Revolade, Jakavi, Fabhalta),Cardiovascular, Renal and Metabolic (Entresto, Leqvio and related CVRM portfolio),Immunology and Neuroscience (Cosentyx, Xolair, Ilaris and related assets),
    ABBVIEUnited StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related),Oncology/Hematology (Imbruvica, Venclexta, Epkinly, Elahere, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev, migraine portfolio),
    APELLIS PHARMACEUTICALSUnited StatesPrivate CompanySYFOVRE – Geographic Atrophy,EMPAVELI – PNH and related indications,Pipeline and collaborations (APL-3007, APL-9099, Beam partnership),
    BIOGENUnited StatesPublic CompanyMultiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neurology (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline linkage),Alzheimer’s and psychiatry (LEQEMBI, ZURZUVAE),
    BAUSCH + LOMBCanadaPublic CompanyVision Care (contact lenses, lens care, OTC eye care, vitamins),Pharmaceuticals (Rx and generic ophthalmics),Surgical (cataract, corneal, vitreous, retinal devices and IOLs),
    ASTELLAS PHARMA INC.JapanPublic CompanyOncology (XTANDI, XOSPATA, VYLOY, PADCEV),Urology (Betanis/Myrabetriq/BETMIGA),Immunology / Transplant (Prograf),
    FORMYCON AGGermanyPublic CompanyRanibizumab biosimilars (ophthalmology),Aflibercept biosimilars (ophthalmology),Ustekinumab biosimilar pipeline/early revenues,
    BIOCONIndiaPublic CompanyBiosimilars (oncology, diabetes, immunology),Generics and APIs,CRDMO (discovery, development, manufacturing services),
    SANDOZ GROUP AGSwitzerlandPublic CompanySmall-molecule generics (oral and injectable),Biosimilars,Specialty and rare disease off-patent medicines,
    SANTEN PHARMACEUTICAL CO., LTD.JapanPublic CompanyGlaucoma & ocular hypertension therapies,Dry eye & keratoconjunctival disease,Allergic conjunctivitis & inflammatory eye disease,
    INNOVENTChinaPublic CompanyOncology immunotherapy (PD-1, CTLA-4, combinations),Oncology targeted therapies and cell therapy,Autoimmune and ophthalmology biologics,
    OUTLOOK THERAPEUTICS, INC.United StatesPublic CompanyONS-5010 (ophthalmic bevacizumab for wet AMD and retinal diseases),Other pipeline / platform and collaboration-derived income,

    REGENERON PHARMACEUTICALS INC.

    Regeneron Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1988 with 15,343 employees. The company focuses on the discovery, development, and commercialization of medicines.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees, operating across pharmaceuticals, consumer health, and agricultural sciences. The company is one of the world's largest diversified life sciences organizations.

    NOVARTIS AG

    Novartis AG is a Swiss public pharmaceutical company founded in 1996 with 75,267 employees. The company develops and manufactures a broad range of innovative medicines and healthcare products.

    ABBVIE

    AbbVie is a United States-based public pharmaceutical company founded in 2012 with 57,000 employees. The company discovers, develops, and markets pharmaceutical products across multiple therapeutic areas.

    APELLIS PHARMACEUTICALS

    Apellis Pharmaceuticals is a United States-based private biopharmaceutical company founded in 2009 with 736 employees. The company focuses on the development of novel therapeutic candidates.

    BIOGEN

    Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. The company discovers, develops, manufactures, and delivers medicines primarily in neurology and immunology.

    BAUSCH + LOMB

    Bausch + Lomb is a Canadian public company founded in 1853 with 13,000 employees specializing in eye health and vision care products. The company is a global leader in the eye care industry.

    ASTELLAS PHARMA INC.

    Astellas Pharma Inc. is a Japanese public pharmaceutical company founded in 1923 with 14,099 employees. The company researches, develops, and commercializes pharmaceutical products worldwide.

    FORMYCON AG

    Formycon AG is a German public biopharmaceutical company founded in 1999 with 203 employees. The company specializes in the development of biosimilar medicines.

    BIOCON

    Biocon is an Indian public biopharmaceutical company founded in 1978 with 16,447 employees. The company develops and manufactures biopharmaceuticals, including biosimilars and small molecule drugs.

    SANDOZ GROUP AG

    Sandoz Group AG is a Swiss public pharmaceutical company founded in 1886 with 22,356 employees. The company is a global leader in generic and biosimilar medicines.

    SANTEN PHARMACEUTICAL CO., LTD.

    Santen Pharmaceutical Co., Ltd. is a Japanese public pharmaceutical company founded in 1890 with 3,968 employees. The company specializes in ophthalmic and other pharmaceutical products.

    INNOVENT

    Innovent is a Chinese public biopharmaceutical company founded in 2011 with 7,502 employees. The company focuses on the research and development of innovative biologics.

    OUTLOOK THERAPEUTICS, INC.

    Outlook Therapeutics, Inc. is a United States-based public biopharmaceutical company founded in 2010 with 17 employees. The company develops and commercializes ophthalmic therapeutic products.

    Reasons to Buy this Report

    • Accurate US Market Sizing : Obtain precise valuation data for the US ophthalmology drugs market with verified figures for 2025 ($5,114.7M) and 2030 forecasts ($6,915.9M), enabling accurate financial planning and investment decisions.
    • Competitive Landscape Intelligence : Understand the competitive dynamics specific to the US market, including major pharmaceutical players, market share distribution, and emerging competitors in retinal and anterior segment drug categories.
    • Growth Driver Analysis : Identify key US-specific growth catalysts including aging demographics, disease prevalence trends, reimbursement policies, and innovation pipelines to inform strategic market entry and expansion strategies.
    • Regulatory & Reimbursement Insights : Gain detailed understanding of US FDA approval pathways, Medicare/Medicaid coverage policies, and insurance reimbursement trends that directly impact market access and profitability for ophthalmology drugs.
    • Segment-Specific Forecasts : Access detailed breakdowns by therapeutic area (retinal diseases, glaucoma, anterior segment) and drug types to identify high-growth segments and optimize product development and commercialization strategies.

    Frequently asked questions

    What is the current size of the US ophthalmology drugs market in 2025?

    The US ophthalmology drugs market is valued at $5,114.7 million in 2025.

    What is the projected size of the US ophthalmology drugs market by 2030?

    The US ophthalmology drugs market is projected to reach $6,915.9 million by 2030.

    What is the growth rate of the US ophthalmology drugs market?

    The US ophthalmology drugs market is expected to grow at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2030.

    What are the primary drivers of growth in the US ophthalmology drugs market?

    Key growth drivers in the US market include an aging population, increasing prevalence of age-related eye diseases, strong pharmaceutical innovation, robust reimbursement frameworks, and rising adoption of biologic and specialty drugs.

    How is the competitive landscape evolving in the US ophthalmology drugs market?

    The US ophthalmology drugs market is experiencing consolidation among major pharmaceutical players and increased competition from biosimilar manufacturers, which is reshaping market dynamics and pricing strategies through 2030.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

    The following is a breakdown of the primary respondents:

    Ophthalmology Drugs Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • A list of the major global players operating in the ophthalmology drugs market was generated.
    • The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
    • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches

    Ophthalmology Drugs Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Patient advocacy organizations
    • Specialty clinics
    • Long-term care facilities
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists    

    Report Objectives

    • To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
    • To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
    • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market

     

    Get the Full Ophthalmology Drugs Market Report

    Full forecast, segment splits, and company analysis for all Ophthalmology Drugs Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status